IDH2 and acute myeloid leukemia: Differentiation induction, and especially monocytic differentiation, seems to be a part of the therapeutic response to several new targeted therapies that are considered for AML therapy (see Section 7), and for the IDH inhibitor enasidenib, such differentiation induction seems to be necessary for an enasidenib-associated increase in venetoclax sensitivity [220].